DNA vaccines are based on plasmid DNA that can be produced at a large scale in bacteria and contain expression promoters and the gene that encodes the spike protein. The advantage of these technologies is the possibility of large-scale production as well as the high stability of plasmid DNA.
Part 1: SARS-CoV-2 Vaccines Development: An Overview
Part 2: Inactivated Vaccines
Part 3: Protein-based Vaccines
Part 4: Viral Vectors
Part 6: Monoclonal Antibodies
This is a snapshot of emerging vaccines during a rapidly evolving pandemic. Any and all information currently available related to COVID-19 is subject to change as more details become available.
This article originally appeared on Univadis, part of the Medscape Professional Network.
© 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: SARS-CoV-2 Vaccines Development: Genetic Vaccines - Medscape - Dec 09, 2020.
Comments